Rheumatoid Arthritis and the Risk of Bipolar Disorder: A Nationwide Population-Based Study

Chih-Chao Hsu¹,²,³, San-Chi Chen²,³, Chia-Jen Liu²,³, Ti Lu¹, Cheng-Che Shen⁴, Yu-Wen Hu³,⁵, Chiu-Mei Yeh⁶, Pan-Ming Chen⁷, Tzeng-Ji Chen⁶,⁸, Li-Yu Hu¹,³

¹Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ²Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ³Institute of Public Health & School of Medicine, National Yang-Ming University, Taipei, Taiwan, ⁴Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiai, Taiwan, ⁵Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, ⁶Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁷Department of Psychiatry, Yuanshan Branch, Taipei Veterans General Hospital, Yilan, Taiwan, ⁸School of Medicine, National Yang-Ming University, Taipei, Taiwan

Abstract

Background: Studies have suggested that chronic inflammation plays an essential role in the pathophysiology of both rheumatoid arthritis (RA) and bipolar disorder. The most common clinical features associated with RA are anxiety and depression. The risk of bipolar disorder among patients with RA has not been characterized adequately.

Objective: To determine the association between RA and the subsequent development of bipolar disorder and examine the risk factors for bipolar disorder among patients with RA.

Methods: We identified patients who were diagnosed with RA in the Taiwan National Health Insurance Research Database. A comparison cohort was created by matching patients without RA with those with RA according to age, sex, and comorbidities. The occurrence of bipolar disorder was evaluated in both cohorts.

Results: The RA cohort consisted of 2,570 patients, and the comparison cohort consisted of 2,570 matched control patients without RA. The incidence of bipolar disorder (incidence rate ratio = 2.13, 95% confidence interval [CI] = 1.12–4.24, \( P = .013 \)) was higher among patients with RA than among control patients. Multivariate, matched regression models revealed that asthma (hazard ratio [HR] = 2.76, 95% CI 1.27–5.96, \( P = .010 \)), liver cirrhosis (HR = 3.81, 95% CI = 1.04–14.02, \( P = .044 \)), and alcohol use disorders (HR = 5.29, 95% CI = 1.71–16.37, \( P = .004 \)) were independent risk factors for the development of bipolar disorder among patients with RA.

Conclusion: RA might increase the incidence of bipolar disorder development. Based on our data, we suggest that, following RA diagnosis, greater attention be focused on women with asthma, liver cirrhosis, and alcohol use disorder. Prospective clinical studies of the relationship between RA and bipolar disorder are warranted.

Introduction

Rheumatoid arthritis (RA), an autoimmune disease, impairs patient health and has wider implications regarding health policy and costs. RA primarily affects the joints, but can also affect the entire body, causing systemic symptoms [1]. Several studies have compared patients with RA and healthy controls and have demonstrated that the mechanism involved in the pathogenesis of RA symptoms is related to chronic inflammation and associated with various cytokines [2].

Interest has grown in the psychiatric aspects of autoimmune diseases characterized by chronic inflammation, which might induce psychiatric illnesses through neuroinflammation and neurotransmitter abnormalities. Autoimmune diseases have been proved to be associated with psychiatric disorders, particularly schizophrenia, major depressive disorder, and bipolar disorder [3]. Studies have identified an association between RA and psychiatric disorders, particularly depressive disorder and schizophrenia [4–6]. However, the existence of this association remains uncertain. Moreover, few studies have investigated the association between RA and bipolar disorder.

Studies have shown that numerous cytokines circulating in plasma might impair the function of the blood-brain barrier [7],
indicating that peripheral inflammation is associated with the upregulation of central nervous system (CNS) inflammation. Several studies have shown that chronic inflammation plays a vital role in the pathophysiology of common mental disorders [8], including bipolar disorder [9]. Therefore, we hypothesized that a history of RA increases the risk of the subsequent onset of bipolar disorder.

To test our hypothesis, we designed a nationwide population-based study to investigate the incidence of bipolar disorder among patients with RA.

Patients and Methods

Data Sources

The Taiwan National Health Insurance (NHI) program offers comprehensive, universal health insurance to all residents of Taiwan. The NHI program covers more than 96% of the residents of Taiwan and is contracted with 99% of all hospitals and clinics in Taiwan [10]. The program provides coverage for outpatient, inpatient, emergency, and traditional Chinese medicine services as well as prescription drugs. Multiple NHI databases, including NHI enrollment files, claims data, and a prescription drug registry, are managed and publicly released by the National Health Research Institutes (NHRI) of Taiwan. The Institutional Review Board of Taipei Veterans General Hospital approved this study (2013-03-035AC). Written consent from the study patients was not obtained because the NHI dataset consists of deidentified secondary data used for research purposes; the Institutional Review Board of Taipei Veterans General Hospital issued a formal written waiver for the need for consent. The National Health Insurance Research Database (NHIRD) is publicly released by the NHRI for research purposes only. Although confidentiality is guaranteed according to the data regulations of the NHRI, studies using this database still must be approved by the ethics committee. Detailed information on data requests is provided on the NHRI Web site (http://nhird.nhri.org.tw). Comments, problems, or requests regarding data application can be sent to the following NHRI email address: nhird@nhri.org.tw.

Study Design and Patients

We conducted a retrospective cohort study of patients who were newly diagnosed with RA between January 1, 2000, and December 31, 2010. We identified RA cases in the Taiwan National Health Insurance Research Database (NHIRD) based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Code 714.0 and included only patients with RA who received a catastrophic illness certificate. The NHI program has specified 30 categories of catastrophic illness (e.g., cancers, hemophilia, autoimmune diseases including RA, and chronic renal failure). Eligible patients can apply for catastrophic illness certificates, and if approved, they are exempted from copayment of related medical costs. In this study, we relied on physicians’ ability to make accurate diagnoses. However, RA diagnosis involves multiple criteria and ruling out diseases with RA-like symptoms. The possibility that RA diagnoses were misclassified was a concern. The issuance of certificates is validated based on a careful review of medical records, laboratory studies, and imaging studies conducted by at least 2 specialists. Therefore, we included only patients with RA who received a catastrophic illness certificate to ensure that RA diagnoses were valid. Several studies that have examined the epidemiology of systemic autoimmune diseases, particularly RA, by using the NHIRD have been published [11,12].

### Table 1. Baseline characteristics of patients with rheumatoid arthritis (RA) and the matched cohort.

| Characteristics                  | Patients with RA n = 2,570 (%) | Matched cohort n = 2,570 (%) | p value |
|----------------------------------|--------------------------------|-----------------------------|---------|
| Median age, years (interquartile range) | 51(41–60)                       | 51(41–60)                   |         |
| Age, years                       |                                |                             |         |
| ≥50                              | 1,358 (52.8)                   | 1,358 (52.8)                | 1.000   |
| <50                              | 1,212 (47.2)                   | 1,212 (47.2)                |         |
| Sex                              |                                |                             |         |
| Male                             | 639 (24.9)                     | 639 (24.9)                  | 1.000   |
| Female                           | 1,931 (75.1)                   | 1,931 (75.1)                |         |
| Comorbidities                    |                                |                             |         |
| Hypertension                     | 790 (30.7)                     | 793 (30.9)                  | 1.000   |
| Dyslipidemia                     | 739 (28.8)                     | 739 (28.8)                  | 0.157   |
| COPD                             | 582 (22.6)                     | 583 (22.7)                  | 0.973   |
| Diabetes mellitus                | 497 (19.3)                     | 497 (19.3)                  | 1.000   |
| Asthma                           | 408 (15.9)                     | 406 (15.8)                  | 0.939   |
| Chronic kidney disease           | 329 (12.8)                     | 329 (12.8)                  | 0.235   |
| Cerebrovascular disease          | 310 (12.1)                     | 309 (12.1)                  | 1.000   |
| Alcohol use disorder             | 65 (2.5)                       | 53 (2.1)                    | <0.001  |
| Liver cirrhosis                  | 64 (2.5)                       | 47 (1.8)                    | 0.103   |
| Malignancies                     | 58 (2.3)                       | 46 (2.1)                    | 0.264   |
| Coronary artery disease          | 27 (1.1)                       | 24 (0.9)                    | 0.928   |
| Median follow-up years (interquartile range) | 6.1(3.4–8.6)                   | 6.1(3.4–8.6)                | 0.673   |
Patients with bipolar disorder between January 1, 2000 and December 31, 2010 were identified based on the ICD-9-CM codes for bipolar disorder (296.0X, 296.1X, 296.4X, 296.5X, 296.6X, 296.7X, 296.80, or 296.89). However, to ensure that the bipolar disorder diagnoses in the database were reliable, we collected data on prescriptions of psychotropic agents for these patients. The role of medication in bipolar disorder treatment is firmly established. Therefore, we excluded patients who were diagnosed with bipolar disorder (according to ICD-9-CM codes) but did not receive any medication. We collected information on the use of drugs approved by the Food and Drug Administration of Taiwan for treating one (or more) phases of bipolar disorder, including acute mania/mixed episodes, bipolar depression, and bipolar maintenance. In addition to mood stabilizers, atypical antipsychotics such as aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone were included. These drugs were classified according to the World Health Organization Anatomical Therapeutic Chemical classification. Only patients who were prescribed these drugs for at least one month were included in our study. Furthermore, patients with mood disorders resulting from a general medical condition (ICD-9-CM Code 293.83) and patients with a history of mood disorders before the enrollment date were excluded from our study.

For each patient with RA in the NHIRD, one patient without RA matched according to age, sex, comorbidities [13], and enrollment date was selected. Although numerous studies have identified several comorbidities as risk factors for RA, based on the inflammation hypothesis proposed in this study, other inflammation-associated comorbidities were considered potential confounders. The exclusion criteria applied to the case cohort were applied to the matched comparison cohort. Both the patients with RA and comparison patients were followed until the development of bipolar disorder, death, or the end of the study period.

Statistical Analysis

The diagnosis of bipolar disorder served as the primary dependent variable. We calculated the bipolar disorder incidence rates (per 10 000 person-y) and the incidence rate ratios (IRRs). The study groups were compared using the \( \chi^2 \) test for categorical variables. The Kaplan-Meier method was used to estimate the cumulative incidence of bipolar disorders, and a Cox proportional hazard model was used to identify risk factors for bipolar disorder in patients with RA. The qualifying criterion for inclusion in the multivariate analysis was a result in the univariate analysis with a P value of less than .1. The Perl programming language (Version 5.12.2) was used to extract data from the databases. Microsoft SQL Server 2005 (Microsoft Corp., Redmond, WA, USA) was used for data linkage, processing, and control sampling. The SPSS, Version 19.0 for Windows (IBM, Armonk, NY, USA) and the SAS, Version 9.2 (SAS Institute, Cary, NC, USA) computer software programs were used to perform all statistical analyses. Comparison results with a P value less than .05 were considered statistically significant.

Results

Patient Characteristics

Table 1 shows demographic and comorbidity data on the patients with RA and control patients. The median age of the patients was 51 years (interquartile range = 41–60 y). The majority of patients in both cohorts were women (75.1%). Diabetes mellitus, chronic obstructive pulmonary disease, asthma, liver cirrhosis, alcohol use disorder, malignancy, chronic kidney disease, cerebral vascular disease, dyslipidemia, hypertension, and coronary artery disease were the most common comorbidities. No statistically significant differences were observed in baseline comorbidity data between the study groups.
Incidence of Bipolar Disorder

The cumulative incidence rates of bipolar disorder are shown in Figure 1. As shown in Table 2, the risk of developing bipolar disorder was significantly higher among patients with RA than among patients in the matched cohort (IRR = 2.13; 95% confidence interval [CI] = 1.12–4.24; \( P = .013 \)). After stratifying patients according to age and sex, we observed that patients with RA under 50 years old exhibited an increased incidence of subsequent bipolar disorder (IRR = 2.26; 95% CI = 0.93–6.00; \( P = .013 \)), even when no obvious statistical difference was observed. Moreover, women with RA exhibited a higher risk of developing subsequent bipolar disorder than did men (IRR = 2.25; 95% CI = 1.10–6.00; \( P = .017 \)). Furthermore, we stratified patients according to follow-up duration and observed that the risk of subsequent bipolar disorder was significantly higher in the first year (IRR = 3.67; 95% CI = 0.97–20.3; \( P = .035 \)) and more than 5 years (IRR = 8.99; 95% CI = 1.25–394.2; \( P = .012 \)) after RA diagnosis. Overall, our study indicated that the incidence of the development of bipolar disorder following RA diagnosis was 20.7 per 10,000 person-years.

Risks Factors for Bipolar Disorder Among Patients with Rheumatoid Arthritis

The results of the univariate and multivariate analyses revealed that asthma (hazard ratio [HR] = 2.76; 95% CI = 1.27–5.96; \( P = .010 \)), liver cirrhosis (HR = 3.81; 95% CI = 1.04–14.02; \( P = .044 \)), alcohol use disorders (HR = 5.29; 95% CI = 1.71–16.37; \( P = .004 \)), and substance abuse (HR = 37.42; 95% CI = 10.31–135.82; \( P < .001 \)) were independent risk factors for the development of bipolar disorder among patients with RA (Table 3).

Discussion

This is the first population-based study to examine RA as a risk factor for bipolar disorder by using a matched cohort and a maximal follow-up period of 10 years. The major finding of our study was the discovery of a higher incidence of subsequent bipolar disorder among patients with RA. Furthermore, women with RA had a higher risk of developing subsequent bipolar disorder than did men, and asthma, liver cirrhosis, and alcohol use disorder are potential risk factors for developing bipolar disorder.

This study revealed that patients with RA were at a higher risk of subsequent bipolar disorder. We hypothesized that this risk is linked to the mechanisms of immune dysfunction. Bipolar disorder development after RA might result from the inflammatory process activated by RA. In 2012, Lampa et al [14] investigated the influence of peripheral chronic joint inflammatory disease in RA on CNS inflammation and revealed that the chronic peripheral inflammatory process activated by RA might cause the upregulation of CNS inflammation. Studies have evidenced that chronic and mild inflammation in the periphery are key contributors to the pathophysiology of CNS inflammation in bipolar disorder [15,16] and that dysregulation of the inflammatory process in the brain triggers and exacerbates atherosclerosis, hypertension, diabetes, obesity, and hyperthyroidism [17–20]. Animal models have indicated that peripheral cytokines reach the brain through various mechanisms, including a leaky brain barrier, active transport, activation of endothelial cells, and binding to cytokine receptors [21]. In short, cytokines created through infectious and inflammatory processes play a vital role in mediating the cross-talk between the immune system and the brain and are therefore possible contributors to the development of several psychiatric diseases, including bipolar disorder [22,23].
However, other studies have revealed that alcohol use disorders improved quality of life among female patients with RA [34,35]. Consumption is associated with a lower incidence of disease and an inflammatory effect might subsequently induce bipolar disorder. In addition, alcohol use disorder was associated with subsequent bipolar disorder in patients with RA. Several studies have indicated that alcohol use disorder was independent risk factors associated with the development of bipolar disorder [33]. In other words, women are more vulnerable to immune dysfunction than men [25–27]. These findings might explain why women with RA had a higher risk of developing bipolar disorder than did women without RA.

When the patients were stratified according to follow-up duration, the incidence of bipolar disorder was significantly higher in the first year and more than 5 years after RA diagnosis. The first result might have been caused by detection bias; patients with symptoms of bipolar disorder might have been diagnosed shortly after RA diagnosis. The second result was compatible with our inflammation hypothesis regarding the association between RA and bipolar disorder. In contrast to acute inflammation, chronic inflammation persists for a prolonged period of time. We hypothesized that, in the long term, the chronic inflammatory process becomes a pathophysiology for the development of bipolar disorder [28].

Our analysis revealed that asthma, liver cirrhosis, and alcohol use disorder were independent risk factors associated with subsequent bipolar disorder in patients with RA. Evidence has indicated that chronic inflammatory processes in asthma and liver cirrhosis, like the pathophysiology of RA, involve cytokine interactions [29–31], and this combined and augmented chronic inflammatory effect might subsequently induce bipolar disorder. Moreover, cytokines that potentially cause depression and anxiety in liver cirrhosis [32] might also be associated with the development of bipolar disorder [33]. In addition, alcohol use disorder was associated with subsequent bipolar disorder in patients with RA. Several studies have indicated that alcohol consumption is associated with a lower incidence of disease and an improved quality of life among female patients with RA [34,35]. However, other studies have revealed that alcohol use disorders and bipolar disorder share certain genetic characteristics and are similar according to neuroimaging and biochemical findings [36,37]. Thus, alcohol use disorder might be an independent risk factor for the development of bipolar disorder among patients with RA.

Our study is the first retrospective study to examine RA as a risk factor for the development of bipolar disorder. A matched cohort study design comprising a population-based cohort of patients with RA and adequate controls for comorbidity constitutes the strengths of our study. However, several limitations that are inherent to the use of claims databases should be considered. First, the diagnosis of RA in the NHIRD was based on the ICD-9-CM code and the issuance of a catastrophic illness certificate. Thus, the severity of RA as a risk factor for subsequent bipolar disorder was not explored. Second, the causal relationship was assessed mainly according to the chronological order in which the 2 conditions were diagnosed. However, both conditions might require long-term treatment, and the possibility that bipolar disorder causes RA cannot be excluded entirely. Third, information was unavailable on several demographic variables such as socioeconomic status, lifestyle, and family history, which might have provided useful information regarding factors that are potentially associated with RA and bipolar disorder [38,39]. Finally, this epidemiologic study was based on an observational design rather than an experimental design. Data on the relationship between the exacerbation of RA and the severity of bipolar disorder in patients with RA were unavailable. Therefore, the direction of causality in the association between the aforementioned possible risk factors and bipolar disorder development among patients with RA could not be determined.

In conclusion, this study revealed that RA increases the incidence of bipolar disorder development, suggesting that the RA-related inflammatory process is associated with increased expression of neuropsychiatric disturbances. Based on our data, we suggest that greater attention be focused on women, particularly those with asthma, liver cirrhosis, and alcohol use disorder. Additional prospective clinical studies on the relationship between RA and bipolar disorder are warranted.

### Table 3. Risk factors for bipolar disorder among patients with rheumatoid arthritis.

| Variables                  | Univariate analysis | Multivariate analysis* |
|----------------------------|---------------------|------------------------|
|                            | HR (95% CI)         | p value                | HR (95% CI)         | p value                |
| Age ≥50 years              | 1.28 (0.63–2.57)    | 0.493                  | 1.77 (0.68–4.58)    | 0.243                  |
| Female                     |                     |                        |                      |
| Comorbidities              |                     |                        |                      |
| Hypertension               | 1.17 (0.55–2.48)    | 0.680                  | 1.79 (0.85–3.79)    | 0.127                  |
| Dyslipidemia               | 0.66 (0.27–1.60)    | 0.356                  | 1.26 (0.55–2.92)    | 0.587                  |
| COPD                       | 3.12 (1.30–6.48)    | 0.002                  | 2.76 (1.27–5.96)    | 0.010                  |
| Diabetes mellitus          | 1.91 (0.79–4.65)    | 0.153                  | 9.87 (3.78–25.80)   | <0.001                 |
| Asthma                     | 0.50 (0.12–2.09)    | 0.340                  | 5.29 (1.71–16.37)   | 0.004                  |
| Chronic kidney disease     | 1.78 (1.24–13.03)   | 0.572                  | 3.81 (1.04–14.02)   | 0.044                  |
| Cerebrovascular disease    | 3.43 (0.47–25.11)   | 0.226                  | 1.79 (0.85–3.79)    | 0.127                  |
| Liver cirrhosis            | 4.87 (1.48–16.01)   | 0.009                  | 3.81 (1.04–14.02)   | 0.044                  |
| Malignancies               |                     |                        |                      |
| Coronary artery disease    |                     |                        |                      |

HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.

*All factors with p < 0.1 in univariate analyses and age were included in the Cox multivariate analysis, and age, sex was enter in the Cox multivariate analysis.

doi:10.1371/journal.pone.0107512.t003
Acknowledgments

We thank Huei-Sing Chang and Cheng-Fang Hong for their technical assistance. The study was based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan and managed by the National Health Research Institutes. The interpretation and conclusion contained herein do not represent the views of the Bureau of National Health Insurance, the Department of Health, or the National Health Research Institutes.

Author Contributions

Conceived and designed the experiments: C-H L-YH S-CC. Performed the experiments: C-JL C-CS Y-YH C-MY. Analyzed the data: C-H L-YH C-JL TL. Contributed reagents/materials/analysis tools: C-JL P-MC T-JC. Contributed to the writing of the manuscript: S-CC C-H L-YH.

References

1. Wasserman AM (2011) Diagnosis and management of rheumatoid arthritis. Am Fam Physician 84: 1245–1252.
2. Calabrese LH (1999) Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc 99: 315–321.
3. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10: 43.
4. Dickens C, McGowan I, Clark-Carter D, Creed F (2002) Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 64: 52–60.
5. Torrey EF, Yolken RH (2001) The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav Immun 15: 401–410.
6. Nicassio PM (2010) Arthritis and psychiatric disorders: disentangling the relationship. J Psychosom Res 68: 183–195.
7. Abbot NJ, Bonnback I, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41–53.
8. Kivimaki M, Shipley MJ, Batty GD, Hamer M, Akbaraly TN, et al. (2013) Long-term inflammation increases risk of common mental disorder: a cohort study. Mol Psychiatry.
9. Stertz L, Magdalhers PV, Kapcinski F (2013) Is bipolar disorder an inflammatory condition? The relevance of microbial activation. Curr Opin Psychiatry 26: 19–26.
10. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, et al. (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308: 1906–1914.
11. Lai NS, Tsai TY, Li CY, Koo M, Yu CL, et al. (2013) Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: A national population-based study. Arthritis Care Res 27: 22146.
12. Lai CH, Lai MS, Lai KL, Chen HH, Chiu YM (2012) Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol 30: 358–363. Epub 2012 Jun 2026.
13. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11: 1.
14. Lampa J, Westman M, Kadetoff D, Agreus AN, Le Maitre E, et al. (2012) Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci U S A 109: 12728–12733.
15. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS (2009) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70: 1078–1090.
16. Hamdani N, Tamouza R, Leboyer M (2012) Immuno-inflammatory markers of bipolar disorder: a review of evidence. Front Biosci (Elite Ed) 4: 2170–2182.
17. Drake C, Boutin H, Jones MS, Denes A, McColl BW, et al. (2011) Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 25: 1113–1122.
18. Ross R (1999) Atherosclerosis is an inflammatory disease. Am Heart J 138: S19–420.
19. Hu LY, Shen CC, Hu YW, Chen MH, Tsai CF, et al. (2013) Hyperthyroidism and risk for bipolar disorder: a nationwide population-based study. PLoS One 8: e73057.
20. Thomsen AF, Kessing LV (2005) Increased risk of hyperthyroidism among patients hospitalized with bipolar disorder. Bipolar Disord 7: 351–357.
21. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732–741.
22. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’anna M, Mascarenhas M, et al. (2009) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 116: 214–217.
23. Rege S, Hodgkinson SJ (2013) Immune dysregulation and autoimmunity in bipolar disorder: Synthesis of the evidence and its clinical application. Aust N Z J Psychiatry 47: 1136–1151.
24. Price AL, Marrazi-Nielsen GR (2012) Bipolar disorders: a review. Am Fam Physician 85: 483–493.
25. Cutolo M, Sulli A, Straub RH (2012) Estrogen metabolism and autoimmunity. Autoimmun Rev 11: A60–A64.
26. Cutolo M, Villaggio B, Seriolo B, Montagna P, Capellino S, et al. (2004) Synovial fluid estrogen in rheumatoid arthritis. Autoimmun Rev 3: 193–196.
27. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, et al. (2004) Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13: 635–639.
28. Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, et al. (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 11: 200.
29. Naik SR, Wala SM (2013) Inflammation, allergy and asthma, complex immune origin diseases: mechanisms and therapeutic agents. Recent Pat Inflamm Allergy Drug Discov 7: 62–95.
30. Shukla S, Shukla H, Kumar S, Aharwal RP, Gupta VK, et al. (2013) Allergy and inflammation: an immunological and therapeutic approach. Recent Pat Inflamm Allergy Drug Discov 7: 135–150.
31. Kocabayoglu P, Friedman SL (2013) Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 5: 217–230.
32. Ko FY, Tsai SJ, Yang AG, Zhou Y, Xiu LM (2013) Association of CD6 T cells with depression and anxiety in patients with liver cirrhosis. Int J Psychiatry Med 45: 15–29.
33. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, et al. (2004) Immunologic variables in acute manic of bipolar disorder. J Neuroimmunol 150: 116–122.
34. Bergman S, Symeonidou S, Andersson ML, Soderlin MK (2013) Alcohol consumption is associated with lower self-reported disease activity and better health-related quality of life in female rheumatoid arthritis patients in Sweden: data from BARFOT, a multicenter study on early RA. BMC Musculoskelet Disord 14: 210.
35. Lu B, Rho YH, Cui J, Iannaccone CK, Frits ML, et al. (2013) Associations of Smoking and Alcohol Consumption with Disease Activity and Functional Status in Rheumatoid Arthritis. J Rheumatol.
36. Farren CK, Hill KP, Weiss RD (2012) Bipolar disorder and alcohol use disorder: a review. Curr Psychiatry Rep 14: 659–666.
37. Petinati HM, O’Brien CP, Dandou WD (2013) Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 170: 23–30.
38. Wamorski JA, Thomas MR, Miklowitz DJ, Allen MH, Winnieoski SR, et al. (2005) Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen Hosp Psychiatry 27: 321–328.
39. Schoeny HK, Birkenaes AB, Vaaler AE, Auestad BH, Malt UF, et al. (2011) Bipolar disorder patients have similar levels of education but lower socio-economic status than the general population. J Affect Disord 129: 68–74.